Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Delirium | 85 | 2024 | 1696 | 12.400 |
Why?
|
Intensive Care Units | 109 | 2024 | 3800 | 7.250 |
Why?
|
Hypnotics and Sedatives | 42 | 2024 | 1191 | 6.210 |
Why?
|
Respiration, Artificial | 57 | 2024 | 2725 | 6.110 |
Why?
|
Critical Care | 47 | 2024 | 2716 | 4.580 |
Why?
|
Critical Illness | 62 | 2024 | 2754 | 4.350 |
Why?
|
Dexmedetomidine | 13 | 2023 | 320 | 4.120 |
Why?
|
Antipsychotic Agents | 28 | 2024 | 3081 | 3.300 |
Why?
|
Haloperidol | 15 | 2024 | 394 | 3.270 |
Why?
|
Propofol | 15 | 2024 | 608 | 3.110 |
Why?
|
Conscious Sedation | 17 | 2024 | 534 | 3.090 |
Why?
|
Pharmacists | 13 | 2023 | 261 | 2.900 |
Why?
|
Neuromuscular Blocking Agents | 4 | 2023 | 132 | 2.600 |
Why?
|
Psychomotor Agitation | 14 | 2024 | 307 | 2.440 |
Why?
|
Pharmacy Service, Hospital | 7 | 2021 | 134 | 2.120 |
Why?
|
Benzodiazepines | 16 | 2022 | 1138 | 2.120 |
Why?
|
Ventilator Weaning | 8 | 2024 | 170 | 1.950 |
Why?
|
Deep Sedation | 7 | 2018 | 119 | 1.560 |
Why?
|
Fentanyl | 6 | 2021 | 450 | 1.240 |
Why?
|
Analgesia | 3 | 2023 | 460 | 1.210 |
Why?
|
Nursing Staff, Hospital | 6 | 2013 | 350 | 1.200 |
Why?
|
Vasopressins | 2 | 2022 | 358 | 1.200 |
Why?
|
Restraint, Physical | 8 | 2019 | 185 | 1.150 |
Why?
|
Vasoconstrictor Agents | 2 | 2024 | 657 | 1.130 |
Why?
|
Proton Pump Inhibitors | 6 | 2008 | 552 | 1.070 |
Why?
|
Anti-Ulcer Agents | 6 | 2008 | 112 | 1.060 |
Why?
|
Tidal Volume | 2 | 2024 | 518 | 1.060 |
Why?
|
Night Care | 2 | 2018 | 28 | 1.050 |
Why?
|
Practice Guidelines as Topic | 18 | 2024 | 7460 | 0.930 |
Why?
|
Midazolam | 5 | 2021 | 267 | 0.930 |
Why?
|
Pain | 11 | 2023 | 5100 | 0.930 |
Why?
|
Analgesics, Opioid | 14 | 2023 | 3838 | 0.920 |
Why?
|
Dibenzothiazepines | 4 | 2013 | 102 | 0.900 |
Why?
|
Clinical Protocols | 13 | 2019 | 1445 | 0.890 |
Why?
|
Humans | 217 | 2024 | 768970 | 0.850 |
Why?
|
Lorazepam | 4 | 2015 | 155 | 0.840 |
Why?
|
Pharmaceutical Services | 2 | 2021 | 143 | 0.770 |
Why?
|
Community Pharmacy Services | 1 | 2021 | 52 | 0.760 |
Why?
|
Anesthetics, Intravenous | 3 | 2009 | 397 | 0.750 |
Why?
|
Pharmacogenetics | 2 | 2023 | 683 | 0.750 |
Why?
|
Anesthesia | 3 | 2022 | 1596 | 0.740 |
Why?
|
2-Pyridinylmethylsulfinylbenzimidazoles | 4 | 2008 | 32 | 0.730 |
Why?
|
Sleep | 10 | 2023 | 4820 | 0.710 |
Why?
|
Professional Role | 3 | 2021 | 316 | 0.710 |
Why?
|
Analgesics | 5 | 2023 | 1071 | 0.710 |
Why?
|
Neuromuscular Blockade | 1 | 2022 | 148 | 0.710 |
Why?
|
Coma | 8 | 2023 | 487 | 0.700 |
Why?
|
Pharmacy | 1 | 2021 | 92 | 0.680 |
Why?
|
Acetaminophen | 1 | 2023 | 556 | 0.660 |
Why?
|
Shock, Septic | 2 | 2017 | 774 | 0.650 |
Why?
|
Melatonin | 1 | 2023 | 670 | 0.590 |
Why?
|
Atracurium | 2 | 2010 | 51 | 0.570 |
Why?
|
Gastric Acid | 3 | 2008 | 98 | 0.560 |
Why?
|
Respiratory Insufficiency | 3 | 2024 | 1241 | 0.550 |
Why?
|
Immobilization | 2 | 2016 | 229 | 0.540 |
Why?
|
Length of Stay | 13 | 2024 | 6526 | 0.540 |
Why?
|
Opioid-Related Disorders | 2 | 2023 | 2188 | 0.540 |
Why?
|
Adult | 75 | 2024 | 223851 | 0.540 |
Why?
|
Publications | 1 | 2019 | 195 | 0.540 |
Why?
|
Mass Screening | 5 | 2013 | 5457 | 0.530 |
Why?
|
Ear Protective Devices | 1 | 2016 | 10 | 0.530 |
Why?
|
Anesthetics | 1 | 2022 | 525 | 0.520 |
Why?
|
Randomized Controlled Trials as Topic | 14 | 2024 | 10400 | 0.520 |
Why?
|
Peptic Ulcer Hemorrhage | 3 | 2005 | 47 | 0.520 |
Why?
|
Long-Term Care | 3 | 2017 | 631 | 0.510 |
Why?
|
Buprenorphine | 1 | 2023 | 667 | 0.500 |
Why?
|
Extracorporeal Membrane Oxygenation | 2 | 2016 | 1483 | 0.480 |
Why?
|
Formularies as Topic | 2 | 2005 | 94 | 0.480 |
Why?
|
Off-Label Use | 1 | 2016 | 185 | 0.470 |
Why?
|
Adrenal Cortex Hormones | 3 | 2015 | 1892 | 0.470 |
Why?
|
Aged | 60 | 2024 | 171786 | 0.460 |
Why?
|
Sepsis | 5 | 2021 | 2610 | 0.460 |
Why?
|
Polypharmacy | 1 | 2017 | 307 | 0.460 |
Why?
|
Stomach Ulcer | 2 | 2008 | 118 | 0.460 |
Why?
|
Drug Costs | 4 | 2014 | 1198 | 0.460 |
Why?
|
Mortality | 2 | 2020 | 2914 | 0.450 |
Why?
|
Physician-Nurse Relations | 1 | 2013 | 20 | 0.440 |
Why?
|
Guideline Adherence | 5 | 2018 | 2241 | 0.440 |
Why?
|
Pneumonia, Bacterial | 2 | 2008 | 320 | 0.430 |
Why?
|
Attitude of Health Personnel | 4 | 2014 | 3928 | 0.430 |
Why?
|
Middle Aged | 70 | 2024 | 223737 | 0.430 |
Why?
|
Double-Blind Method | 13 | 2021 | 12467 | 0.420 |
Why?
|
Acute Disease | 11 | 2019 | 7245 | 0.420 |
Why?
|
Male | 88 | 2024 | 365203 | 0.420 |
Why?
|
Time Factors | 17 | 2024 | 40261 | 0.410 |
Why?
|
Drug Information Services | 1 | 2012 | 51 | 0.410 |
Why?
|
Language | 1 | 2022 | 1559 | 0.410 |
Why?
|
Mentors | 1 | 2018 | 672 | 0.400 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2017 | 3253 | 0.400 |
Why?
|
Perception | 2 | 2017 | 1209 | 0.400 |
Why?
|
Torsades de Pointes | 1 | 2013 | 78 | 0.400 |
Why?
|
Hospital Mortality | 9 | 2023 | 5369 | 0.390 |
Why?
|
Long QT Syndrome | 1 | 2016 | 472 | 0.390 |
Why?
|
Quality Improvement | 7 | 2020 | 3860 | 0.390 |
Why?
|
Female | 87 | 2024 | 397515 | 0.390 |
Why?
|
Drugs, Generic | 1 | 2017 | 455 | 0.380 |
Why?
|
Positive-Pressure Respiration | 2 | 2024 | 713 | 0.380 |
Why?
|
Kynurenine | 1 | 2012 | 142 | 0.370 |
Why?
|
Peptic Ulcer | 2 | 2005 | 215 | 0.370 |
Why?
|
Education, Nursing, Continuing | 2 | 2008 | 69 | 0.370 |
Why?
|
Checklist | 3 | 2020 | 841 | 0.360 |
Why?
|
Antihypertensive Agents | 5 | 2010 | 2027 | 0.360 |
Why?
|
Publishing | 1 | 2018 | 837 | 0.360 |
Why?
|
Prospective Studies | 31 | 2022 | 54962 | 0.350 |
Why?
|
Medical Staff, Hospital | 3 | 2013 | 603 | 0.350 |
Why?
|
Acute Lung Injury | 1 | 2014 | 378 | 0.350 |
Why?
|
Substance Withdrawal Syndrome | 2 | 2012 | 628 | 0.350 |
Why?
|
Biomedical Research | 4 | 2024 | 3463 | 0.340 |
Why?
|
Methadone | 1 | 2012 | 317 | 0.340 |
Why?
|
Tryptophan | 1 | 2012 | 482 | 0.340 |
Why?
|
Skilled Nursing Facilities | 3 | 2024 | 406 | 0.340 |
Why?
|
Psychiatric Status Rating Scales | 5 | 2015 | 6030 | 0.330 |
Why?
|
Hospitalization | 7 | 2024 | 10847 | 0.330 |
Why?
|
Professional Practice | 1 | 2011 | 314 | 0.330 |
Why?
|
Infusions, Intravenous | 7 | 2017 | 2231 | 0.330 |
Why?
|
Omeprazole | 2 | 2006 | 106 | 0.320 |
Why?
|
Health Knowledge, Attitudes, Practice | 4 | 2017 | 4056 | 0.320 |
Why?
|
Thrombocytopenia | 1 | 2016 | 1181 | 0.310 |
Why?
|
Education, Pharmacy, Graduate | 2 | 2019 | 8 | 0.310 |
Why?
|
Laryngeal Edema | 1 | 2008 | 21 | 0.300 |
Why?
|
Brain Diseases | 2 | 2020 | 1558 | 0.300 |
Why?
|
Nursing Assessment | 1 | 2008 | 107 | 0.290 |
Why?
|
Patient Readmission | 3 | 2019 | 3313 | 0.290 |
Why?
|
Stress, Psychological | 2 | 2022 | 4530 | 0.290 |
Why?
|
Enoxaparin | 2 | 2001 | 391 | 0.290 |
Why?
|
Nurses | 1 | 2017 | 2501 | 0.280 |
Why?
|
Dose-Response Relationship, Drug | 6 | 2018 | 10765 | 0.280 |
Why?
|
Netherlands | 6 | 2021 | 2277 | 0.280 |
Why?
|
Physicians | 2 | 2022 | 4607 | 0.270 |
Why?
|
Severe Acute Respiratory Syndrome | 1 | 2007 | 136 | 0.270 |
Why?
|
Intubation, Gastrointestinal | 2 | 2008 | 166 | 0.270 |
Why?
|
Hypertension | 7 | 2015 | 8617 | 0.260 |
Why?
|
United States | 26 | 2024 | 73186 | 0.250 |
Why?
|
Anti-Bacterial Agents | 3 | 2017 | 7478 | 0.250 |
Why?
|
APACHE | 7 | 2023 | 268 | 0.250 |
Why?
|
Protein C | 2 | 2003 | 134 | 0.250 |
Why?
|
Wounds and Injuries | 4 | 2015 | 2517 | 0.250 |
Why?
|
Anti-Infective Agents | 2 | 2003 | 984 | 0.250 |
Why?
|
Cohort Studies | 14 | 2023 | 41808 | 0.240 |
Why?
|
Circadian Rhythm | 2 | 2016 | 2593 | 0.240 |
Why?
|
Colloids | 1 | 2005 | 126 | 0.240 |
Why?
|
Academic Medical Centers | 6 | 2015 | 2784 | 0.240 |
Why?
|
Retrospective Studies | 22 | 2024 | 81903 | 0.240 |
Why?
|
Psychological Tests | 1 | 2007 | 642 | 0.240 |
Why?
|
Evidence-Based Medicine | 2 | 2017 | 3709 | 0.240 |
Why?
|
Enteral Nutrition | 3 | 2022 | 802 | 0.240 |
Why?
|
Fenoldopam | 1 | 2004 | 6 | 0.230 |
Why?
|
Dementia | 6 | 2024 | 2741 | 0.230 |
Why?
|
Pharmaceutical Preparations | 1 | 2012 | 1088 | 0.230 |
Why?
|
Incidence | 6 | 2019 | 21547 | 0.230 |
Why?
|
Logistic Models | 8 | 2023 | 13318 | 0.230 |
Why?
|
Nitroprusside | 1 | 2004 | 272 | 0.220 |
Why?
|
Research Design | 6 | 2024 | 6214 | 0.220 |
Why?
|
Coronary Artery Bypass | 1 | 2013 | 2194 | 0.220 |
Why?
|
Drug Therapy, Combination | 4 | 2019 | 6320 | 0.220 |
Why?
|
Pilot Projects | 6 | 2020 | 8748 | 0.220 |
Why?
|
Cross Infection | 3 | 2008 | 1425 | 0.210 |
Why?
|
Sodium Chloride | 1 | 2005 | 584 | 0.210 |
Why?
|
Pancuronium | 1 | 2002 | 44 | 0.210 |
Why?
|
Gram-Negative Bacteria | 1 | 2004 | 275 | 0.210 |
Why?
|
Feasibility Studies | 4 | 2019 | 5323 | 0.210 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2006 | 496 | 0.200 |
Why?
|
Respiration | 3 | 2024 | 1668 | 0.200 |
Why?
|
ROC Curve | 4 | 2023 | 3629 | 0.200 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2004 | 238 | 0.200 |
Why?
|
Hypertriglyceridemia | 1 | 2005 | 293 | 0.200 |
Why?
|
Tachyphylaxis | 1 | 2002 | 54 | 0.200 |
Why?
|
Drug Monitoring | 3 | 2011 | 965 | 0.200 |
Why?
|
Albumins | 1 | 2005 | 577 | 0.200 |
Why?
|
Drug Therapy | 2 | 2009 | 504 | 0.190 |
Why?
|
Drug Utilization | 3 | 2019 | 1191 | 0.190 |
Why?
|
Psychometrics | 3 | 2013 | 3066 | 0.190 |
Why?
|
Risk Factors | 20 | 2022 | 74976 | 0.190 |
Why?
|
Stress, Physiological | 2 | 1999 | 1408 | 0.190 |
Why?
|
Gastrointestinal Diseases | 2 | 2010 | 1204 | 0.180 |
Why?
|
Paralysis | 1 | 2022 | 250 | 0.180 |
Why?
|
Fluoroquinolones | 1 | 2003 | 309 | 0.180 |
Why?
|
Virulence Factors | 1 | 2004 | 502 | 0.180 |
Why?
|
Nimodipine | 1 | 2000 | 57 | 0.180 |
Why?
|
Fluid Therapy | 1 | 2005 | 587 | 0.180 |
Why?
|
Parenteral Nutrition | 1 | 2005 | 663 | 0.180 |
Why?
|
Shock, Traumatic | 1 | 2000 | 22 | 0.180 |
Why?
|
Gastroesophageal Reflux | 1 | 2008 | 836 | 0.180 |
Why?
|
Treatment Outcome | 18 | 2021 | 65480 | 0.180 |
Why?
|
Venous Thrombosis | 2 | 2001 | 1321 | 0.170 |
Why?
|
Wound Infection | 1 | 2002 | 243 | 0.170 |
Why?
|
Gastrointestinal Agents | 1 | 2005 | 510 | 0.170 |
Why?
|
Multiple Organ Failure | 1 | 2003 | 387 | 0.170 |
Why?
|
Wounds, Penetrating | 1 | 2002 | 316 | 0.170 |
Why?
|
Guidelines as Topic | 3 | 2020 | 1399 | 0.170 |
Why?
|
Intubation, Intratracheal | 1 | 2008 | 1359 | 0.170 |
Why?
|
Serine Endopeptidases | 1 | 2004 | 1027 | 0.160 |
Why?
|
Abdominal Injuries | 1 | 2002 | 362 | 0.160 |
Why?
|
Cost-Benefit Analysis | 7 | 2019 | 5544 | 0.160 |
Why?
|
Communication | 1 | 2013 | 3908 | 0.160 |
Why?
|
Drug Administration Schedule | 5 | 2013 | 4862 | 0.160 |
Why?
|
Syndrome | 3 | 2010 | 3274 | 0.160 |
Why?
|
Florida | 1 | 2020 | 430 | 0.160 |
Why?
|
Candidiasis | 2 | 2001 | 367 | 0.160 |
Why?
|
Medication Reconciliation | 1 | 2020 | 153 | 0.160 |
Why?
|
Neuropsychological Tests | 1 | 2012 | 7148 | 0.150 |
Why?
|
Administration, Oral | 4 | 2010 | 4040 | 0.150 |
Why?
|
Pancreatitis | 1 | 2005 | 1087 | 0.150 |
Why?
|
Prisons | 1 | 2020 | 179 | 0.150 |
Why?
|
Withholding Treatment | 2 | 2013 | 620 | 0.150 |
Why?
|
Quarantine | 1 | 2020 | 186 | 0.150 |
Why?
|
Contact Tracing | 1 | 2020 | 275 | 0.150 |
Why?
|
Energy Intake | 1 | 2005 | 2146 | 0.150 |
Why?
|
Patient Care Team | 4 | 2020 | 2528 | 0.140 |
Why?
|
Students, Pharmacy | 1 | 2017 | 17 | 0.140 |
Why?
|
Clinical Competence | 2 | 2017 | 4860 | 0.140 |
Why?
|
Patient Transfer | 2 | 2016 | 792 | 0.140 |
Why?
|
Antibiotic Prophylaxis | 1 | 2002 | 641 | 0.140 |
Why?
|
Evidence-Based Practice | 4 | 2019 | 500 | 0.140 |
Why?
|
Calcium Channel Blockers | 1 | 2000 | 691 | 0.140 |
Why?
|
Hospitals, Teaching | 2 | 2020 | 1159 | 0.140 |
Why?
|
Cooperative Behavior | 3 | 2019 | 1515 | 0.140 |
Why?
|
Pharmacoepidemiology | 1 | 2020 | 351 | 0.140 |
Why?
|
Amphotericin B | 1 | 1997 | 143 | 0.140 |
Why?
|
Drug Administration Routes | 2 | 2008 | 151 | 0.140 |
Why?
|
Hyperglycemia | 1 | 2005 | 1389 | 0.140 |
Why?
|
Hospital Bed Capacity, 300 to 499 | 2 | 2008 | 55 | 0.140 |
Why?
|
Homes for the Aged | 1 | 2019 | 273 | 0.130 |
Why?
|
Multiple Trauma | 1 | 1999 | 369 | 0.130 |
Why?
|
Diarrhea | 2 | 2022 | 1320 | 0.130 |
Why?
|
Aged, 80 and over | 12 | 2024 | 59739 | 0.130 |
Why?
|
Hypotension | 1 | 2022 | 888 | 0.130 |
Why?
|
Patient Participation | 2 | 2017 | 1448 | 0.130 |
Why?
|
Recombinant Proteins | 2 | 2003 | 6512 | 0.130 |
Why?
|
Sleep Stages | 1 | 2020 | 706 | 0.130 |
Why?
|
Teaching Rounds | 1 | 2020 | 282 | 0.130 |
Why?
|
Prevalence | 4 | 2021 | 15879 | 0.130 |
Why?
|
Bed Rest | 1 | 2016 | 83 | 0.130 |
Why?
|
Multivariate Analysis | 5 | 2020 | 12095 | 0.130 |
Why?
|
Multicenter Studies as Topic | 4 | 2023 | 1737 | 0.130 |
Why?
|
Data Collection | 3 | 2013 | 3324 | 0.120 |
Why?
|
Activities of Daily Living | 1 | 2024 | 2434 | 0.120 |
Why?
|
California | 1 | 2019 | 1443 | 0.120 |
Why?
|
Bradycardia | 2 | 2022 | 305 | 0.120 |
Why?
|
Career Mobility | 1 | 2017 | 262 | 0.120 |
Why?
|
Consciousness | 2 | 2012 | 602 | 0.120 |
Why?
|
Documentation | 1 | 2021 | 917 | 0.120 |
Why?
|
Respiratory Function Tests | 1 | 2019 | 1694 | 0.120 |
Why?
|
Cholinergic Antagonists | 1 | 2015 | 167 | 0.120 |
Why?
|
Cerebrovascular Disorders | 1 | 2011 | 1486 | 0.120 |
Why?
|
Enzyme Inhibitors | 1 | 2005 | 3726 | 0.120 |
Why?
|
Caregivers | 2 | 2013 | 2308 | 0.120 |
Why?
|
Registries | 3 | 2011 | 8384 | 0.120 |
Why?
|
Acupuncture Therapy | 1 | 2019 | 486 | 0.120 |
Why?
|
Pain Measurement | 3 | 2019 | 3586 | 0.110 |
Why?
|
Postoperative Complications | 6 | 2022 | 15889 | 0.110 |
Why?
|
Societies, Medical | 2 | 2023 | 3968 | 0.110 |
Why?
|
Placebo Effect | 1 | 2018 | 518 | 0.110 |
Why?
|
Markov Chains | 2 | 2015 | 979 | 0.110 |
Why?
|
Noise | 1 | 2016 | 295 | 0.110 |
Why?
|
Patient Care | 1 | 2019 | 629 | 0.110 |
Why?
|
Linear Models | 3 | 2016 | 5891 | 0.110 |
Why?
|
Fever | 1 | 2021 | 1619 | 0.110 |
Why?
|
Biological Availability | 2 | 2005 | 392 | 0.110 |
Why?
|
Hospitals, Chronic Disease | 1 | 2013 | 8 | 0.110 |
Why?
|
Sleep Deprivation | 1 | 2020 | 848 | 0.110 |
Why?
|
Professional-Family Relations | 1 | 2017 | 501 | 0.110 |
Why?
|
Delphi Technique | 3 | 2021 | 890 | 0.110 |
Why?
|
Pain, Postoperative | 1 | 2023 | 1767 | 0.110 |
Why?
|
Societies, Pharmaceutical | 1 | 2012 | 3 | 0.110 |
Why?
|
Dihematoporphyrin Ether | 1 | 2012 | 33 | 0.100 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 8055 | 0.100 |
Why?
|
Alzheimer Disease | 3 | 2024 | 8760 | 0.100 |
Why?
|
Neurotransmitter Agents | 1 | 2017 | 663 | 0.100 |
Why?
|
Survival Rate | 4 | 2019 | 12873 | 0.100 |
Why?
|
Morphine | 2 | 2015 | 658 | 0.100 |
Why?
|
Acidosis | 2 | 2015 | 271 | 0.100 |
Why?
|
North America | 3 | 2023 | 1290 | 0.100 |
Why?
|
Canada | 3 | 2019 | 2130 | 0.100 |
Why?
|
Tennessee | 1 | 2011 | 123 | 0.100 |
Why?
|
Time Management | 1 | 2011 | 53 | 0.100 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 1999 | 1126 | 0.100 |
Why?
|
Severity of Illness Index | 7 | 2023 | 15951 | 0.100 |
Why?
|
Pandemics | 2 | 2023 | 8749 | 0.100 |
Why?
|
Boston | 2 | 2019 | 9377 | 0.100 |
Why?
|
Drug Stability | 2 | 2005 | 292 | 0.090 |
Why?
|
Cross-Sectional Studies | 6 | 2019 | 26395 | 0.090 |
Why?
|
Heparin | 1 | 1998 | 1636 | 0.090 |
Why?
|
Postoperative Care | 2 | 2013 | 1481 | 0.090 |
Why?
|
Bacterial Proteins | 1 | 2004 | 3840 | 0.090 |
Why?
|
North Carolina | 1 | 2012 | 329 | 0.090 |
Why?
|
Nursing Homes | 1 | 2019 | 1084 | 0.090 |
Why?
|
Disease Outbreaks | 1 | 2020 | 1761 | 0.090 |
Why?
|
Michigan | 1 | 2011 | 336 | 0.090 |
Why?
|
Factor Analysis, Statistical | 1 | 2013 | 1002 | 0.090 |
Why?
|
Area Under Curve | 3 | 2018 | 1645 | 0.090 |
Why?
|
Biliary Tract Neoplasms | 1 | 2012 | 187 | 0.090 |
Why?
|
Allopurinol | 1 | 1992 | 202 | 0.090 |
Why?
|
Research | 1 | 2019 | 1981 | 0.090 |
Why?
|
Injections, Intravenous | 3 | 2009 | 1379 | 0.090 |
Why?
|
Excipients | 1 | 2010 | 98 | 0.090 |
Why?
|
Probability | 1 | 2015 | 2483 | 0.090 |
Why?
|
Nurse-Patient Relations | 1 | 2010 | 101 | 0.080 |
Why?
|
Internet | 2 | 2012 | 3112 | 0.080 |
Why?
|
Phenylcarbamates | 1 | 2009 | 38 | 0.080 |
Why?
|
Mental Recall | 1 | 2015 | 1226 | 0.080 |
Why?
|
Nursing Administration Research | 1 | 2008 | 21 | 0.080 |
Why?
|
Trauma Centers | 2 | 2005 | 951 | 0.080 |
Why?
|
Gastric Acidity Determination | 1 | 2008 | 56 | 0.080 |
Why?
|
Quality of Health Care | 2 | 2020 | 4339 | 0.080 |
Why?
|
New England | 1 | 2011 | 1058 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2023 | 2666 | 0.080 |
Why?
|
Photosensitizing Agents | 1 | 2012 | 630 | 0.070 |
Why?
|
Decision Support Techniques | 1 | 2018 | 2008 | 0.070 |
Why?
|
Endocrine System Diseases | 1 | 2010 | 250 | 0.070 |
Why?
|
Proportional Hazards Models | 2 | 2020 | 12562 | 0.070 |
Why?
|
Muscle Weakness | 1 | 2010 | 413 | 0.070 |
Why?
|
Disease Management | 2 | 2016 | 2537 | 0.070 |
Why?
|
Psychotherapy | 1 | 2017 | 1654 | 0.070 |
Why?
|
Models, Theoretical | 1 | 2019 | 3580 | 0.070 |
Why?
|
Blood Pressure | 4 | 2011 | 8544 | 0.070 |
Why?
|
Medical Records | 1 | 2013 | 1411 | 0.070 |
Why?
|
Consensus | 3 | 2021 | 3214 | 0.070 |
Why?
|
Inpatients | 1 | 2019 | 2569 | 0.070 |
Why?
|
Motivation | 1 | 2017 | 2025 | 0.070 |
Why?
|
Proton Pumps | 1 | 2006 | 29 | 0.070 |
Why?
|
Placebos | 1 | 2011 | 1667 | 0.070 |
Why?
|
Dexamethasone | 1 | 2014 | 1965 | 0.070 |
Why?
|
Public Health | 1 | 2020 | 2680 | 0.070 |
Why?
|
Infusions, Parenteral | 1 | 2006 | 396 | 0.070 |
Why?
|
Quality of Life | 4 | 2023 | 13510 | 0.070 |
Why?
|
Family | 1 | 2017 | 3208 | 0.070 |
Why?
|
Robotics | 1 | 2013 | 826 | 0.070 |
Why?
|
Australia | 2 | 2021 | 1265 | 0.060 |
Why?
|
Photochemotherapy | 1 | 2012 | 830 | 0.060 |
Why?
|
Clinical Pharmacy Information Systems | 1 | 2006 | 102 | 0.060 |
Why?
|
Safety | 2 | 2008 | 1161 | 0.060 |
Why?
|
Predictive Value of Tests | 4 | 2020 | 15471 | 0.060 |
Why?
|
Statistics, Nonparametric | 3 | 2017 | 2862 | 0.060 |
Why?
|
Program Development | 1 | 2012 | 1300 | 0.060 |
Why?
|
Muscular Diseases | 1 | 2010 | 553 | 0.060 |
Why?
|
Health Care Surveys | 1 | 2013 | 2437 | 0.060 |
Why?
|
MEDLINE | 1 | 2005 | 119 | 0.060 |
Why?
|
Drug Storage | 1 | 2005 | 52 | 0.060 |
Why?
|
Plasma Substitutes | 1 | 2005 | 58 | 0.060 |
Why?
|
Capsules | 1 | 2005 | 193 | 0.060 |
Why?
|
Tablets | 1 | 2005 | 149 | 0.060 |
Why?
|
Hyperlipidemias | 1 | 2010 | 773 | 0.060 |
Why?
|
Anti-Inflammatory Agents | 1 | 2014 | 1811 | 0.060 |
Why?
|
Isotonic Solutions | 1 | 2005 | 120 | 0.060 |
Why?
|
Analysis of Variance | 1 | 2013 | 6236 | 0.060 |
Why?
|
Immune System | 1 | 2010 | 800 | 0.060 |
Why?
|
Lung | 2 | 2019 | 10099 | 0.060 |
Why?
|
Prognosis | 5 | 2023 | 30046 | 0.060 |
Why?
|
Problem-Based Learning | 1 | 2007 | 360 | 0.060 |
Why?
|
United States Food and Drug Administration | 1 | 2012 | 1672 | 0.060 |
Why?
|
Fatty Liver | 1 | 2010 | 810 | 0.060 |
Why?
|
Reproducibility of Results | 3 | 2013 | 20245 | 0.050 |
Why?
|
Program Evaluation | 1 | 2012 | 2508 | 0.050 |
Why?
|
Food-Drug Interactions | 1 | 2003 | 26 | 0.050 |
Why?
|
Thiazoles | 1 | 2011 | 1542 | 0.050 |
Why?
|
Genome-Wide Association Study | 1 | 2023 | 12801 | 0.050 |
Why?
|
Diffusion of Innovation | 1 | 2008 | 732 | 0.050 |
Why?
|
Medicare | 4 | 2024 | 6888 | 0.050 |
Why?
|
Chronic Disease | 2 | 2016 | 9384 | 0.050 |
Why?
|
Anticoagulants | 1 | 1998 | 4850 | 0.050 |
Why?
|
Clonidine | 1 | 2023 | 170 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3118 | 0.050 |
Why?
|
Cardiovascular System | 1 | 2010 | 841 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3241 | 0.050 |
Why?
|
Laryngoscopy | 1 | 2008 | 714 | 0.050 |
Why?
|
Hospitals | 3 | 2021 | 3904 | 0.050 |
Why?
|
Quality Assurance, Health Care | 1 | 2012 | 2182 | 0.050 |
Why?
|
Recovery of Function | 2 | 2024 | 2990 | 0.050 |
Why?
|
Digestive System | 1 | 2002 | 244 | 0.050 |
Why?
|
Emergency Service, Hospital | 1 | 2011 | 7957 | 0.050 |
Why?
|
Longitudinal Studies | 1 | 2018 | 14794 | 0.050 |
Why?
|
Scotland | 1 | 2021 | 142 | 0.050 |
Why?
|
District of Columbia | 1 | 2021 | 159 | 0.050 |
Why?
|
Observer Variation | 1 | 2007 | 2623 | 0.050 |
Why?
|
Administration, Inhalation | 1 | 2024 | 1169 | 0.050 |
Why?
|
Isoflurane | 1 | 2024 | 384 | 0.050 |
Why?
|
Respiratory Mucosa | 1 | 2004 | 439 | 0.050 |
Why?
|
Cross-Over Studies | 2 | 2008 | 2108 | 0.050 |
Why?
|
Brief Psychiatric Rating Scale | 1 | 2020 | 108 | 0.040 |
Why?
|
Models, Statistical | 1 | 2015 | 5110 | 0.040 |
Why?
|
Cognition | 3 | 2024 | 7081 | 0.040 |
Why?
|
Postoperative Period | 1 | 2005 | 1830 | 0.040 |
Why?
|
Economics, Hospital | 1 | 2003 | 210 | 0.040 |
Why?
|
Ireland | 1 | 2020 | 170 | 0.040 |
Why?
|
Educational Measurement | 1 | 2007 | 1260 | 0.040 |
Why?
|
Risk Assessment | 4 | 2013 | 24333 | 0.040 |
Why?
|
Health Services Needs and Demand | 1 | 2008 | 1407 | 0.040 |
Why?
|
Diagnostic Errors | 1 | 2007 | 1281 | 0.040 |
Why?
|
Piperazines | 1 | 2011 | 2553 | 0.040 |
Why?
|
Adrenergic alpha-2 Receptor Agonists | 1 | 2021 | 92 | 0.040 |
Why?
|
Massachusetts | 1 | 2013 | 8894 | 0.040 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2020 | 118 | 0.040 |
Why?
|
Arrhythmias, Cardiac | 1 | 2009 | 2258 | 0.040 |
Why?
|
Cytochrome P-450 CYP2D6 | 1 | 2020 | 108 | 0.040 |
Why?
|
Alkalosis | 1 | 1999 | 55 | 0.040 |
Why?
|
Nervous System Diseases | 1 | 2010 | 1665 | 0.040 |
Why?
|
Anesthetics, Inhalation | 1 | 2024 | 573 | 0.040 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2003 | 1536 | 0.040 |
Why?
|
Advisory Committees | 1 | 2003 | 797 | 0.040 |
Why?
|
Kidney Diseases | 1 | 2010 | 2100 | 0.040 |
Why?
|
Poland | 1 | 2019 | 197 | 0.040 |
Why?
|
Hospital Bed Capacity, under 100 | 1 | 1998 | 6 | 0.040 |
Why?
|
Decision Making | 1 | 2013 | 3953 | 0.040 |
Why?
|
Cognition Disorders | 1 | 2013 | 3985 | 0.040 |
Why?
|
Acetazolamide | 1 | 1999 | 98 | 0.040 |
Why?
|
Sucralfate | 1 | 1998 | 12 | 0.040 |
Why?
|
Carbonic Anhydrase Inhibitors | 1 | 1999 | 92 | 0.040 |
Why?
|
Qualitative Research | 1 | 2010 | 3143 | 0.040 |
Why?
|
Sensitivity and Specificity | 1 | 2014 | 14752 | 0.040 |
Why?
|
Saudi Arabia | 1 | 2019 | 212 | 0.040 |
Why?
|
Age Factors | 4 | 2017 | 18435 | 0.040 |
Why?
|
Internship and Residency | 1 | 2019 | 5956 | 0.040 |
Why?
|
Portugal | 1 | 2018 | 91 | 0.040 |
Why?
|
Belgium | 1 | 2018 | 119 | 0.040 |
Why?
|
Costs and Cost Analysis | 1 | 2004 | 1669 | 0.040 |
Why?
|
Cardiac Surgical Procedures | 2 | 2014 | 3683 | 0.040 |
Why?
|
Anxiety | 1 | 2013 | 4672 | 0.040 |
Why?
|
Schools, Pharmacy | 1 | 2017 | 5 | 0.040 |
Why?
|
Monte Carlo Method | 1 | 2003 | 1262 | 0.040 |
Why?
|
Triiodothyronine | 1 | 2019 | 492 | 0.040 |
Why?
|
Trauma Severity Indices | 1 | 1999 | 479 | 0.040 |
Why?
|
Histamine H2 Antagonists | 1 | 1998 | 169 | 0.030 |
Why?
|
Quality Indicators, Health Care | 1 | 2007 | 1812 | 0.030 |
Why?
|
Gastroscopy | 1 | 1998 | 213 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2002 | 2932 | 0.030 |
Why?
|
Odds Ratio | 2 | 2021 | 9684 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2021 | 812 | 0.030 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2001 | 621 | 0.030 |
Why?
|
Diuretics | 1 | 1999 | 614 | 0.030 |
Why?
|
Patient Selection | 1 | 2008 | 4265 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2023 | 2732 | 0.030 |
Why?
|
Polysomnography | 1 | 2023 | 1871 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 2002 | 3438 | 0.030 |
Why?
|
Denmark | 1 | 2018 | 776 | 0.030 |
Why?
|
Hydromorphone | 1 | 2015 | 70 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2012 | 22296 | 0.030 |
Why?
|
Poisson Distribution | 1 | 2015 | 508 | 0.030 |
Why?
|
Fat Emulsions, Intravenous | 1 | 1997 | 314 | 0.030 |
Why?
|
Patient Satisfaction | 1 | 2006 | 3492 | 0.030 |
Why?
|
Hydrocephalus | 1 | 2000 | 770 | 0.030 |
Why?
|
Interprofessional Relations | 1 | 2020 | 997 | 0.030 |
Why?
|
Intraoperative Period | 1 | 2014 | 513 | 0.030 |
Why?
|
Comorbidity | 3 | 2015 | 10592 | 0.030 |
Why?
|
Follow-Up Studies | 3 | 2019 | 39394 | 0.030 |
Why?
|
Ventilators, Mechanical | 1 | 2015 | 292 | 0.030 |
Why?
|
Creatinine | 1 | 2019 | 1917 | 0.030 |
Why?
|
Adolescent | 4 | 2019 | 89244 | 0.030 |
Why?
|
Hypoglycemic Agents | 1 | 2005 | 3110 | 0.030 |
Why?
|
Subarachnoid Hemorrhage | 1 | 2000 | 1039 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2012 | 167 | 0.030 |
Why?
|
Fibrinolytic Agents | 1 | 2001 | 2080 | 0.020 |
Why?
|
Databases, Factual | 1 | 2007 | 8094 | 0.020 |
Why?
|
Anticonvulsants | 1 | 2022 | 1924 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2001 | 3232 | 0.020 |
Why?
|
Forms and Records Control | 1 | 1992 | 158 | 0.020 |
Why?
|
Medication Systems, Hospital | 1 | 1992 | 154 | 0.020 |
Why?
|
Insulin | 1 | 2005 | 6610 | 0.020 |
Why?
|
Ontario | 1 | 1992 | 403 | 0.020 |
Why?
|
Hydrocortisone | 1 | 2019 | 1841 | 0.020 |
Why?
|
Bilirubin | 1 | 2012 | 438 | 0.020 |
Why?
|
Medical Audit | 1 | 1992 | 454 | 0.020 |
Why?
|
Device Removal | 1 | 2015 | 643 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2021 | 6547 | 0.020 |
Why?
|
Survival Analysis | 1 | 2021 | 10115 | 0.020 |
Why?
|
Education, Pharmacy | 1 | 2007 | 38 | 0.020 |
Why?
|
Metabolic Clearance Rate | 1 | 2008 | 363 | 0.020 |
Why?
|
Regression Analysis | 1 | 2015 | 6346 | 0.020 |
Why?
|
Patient Discharge | 1 | 2019 | 3491 | 0.020 |
Why?
|
Genotype | 1 | 2020 | 13048 | 0.020 |
Why?
|
Health Care Costs | 1 | 1998 | 3270 | 0.020 |
Why?
|
Heart Failure | 1 | 2009 | 11879 | 0.020 |
Why?
|
Morbidity | 1 | 2010 | 1757 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2010 | 15661 | 0.010 |
Why?
|
Medication Errors | 1 | 2009 | 785 | 0.010 |
Why?
|
Arthritis, Rheumatoid | 1 | 1999 | 3780 | 0.010 |
Why?
|
Health Behavior | 1 | 2015 | 2649 | 0.010 |
Why?
|
Alcohol Drinking | 1 | 2015 | 4045 | 0.010 |
Why?
|
Child | 2 | 2008 | 80960 | 0.010 |
Why?
|
Health Status | 1 | 2015 | 4095 | 0.010 |
Why?
|
Bipolar Disorder | 1 | 2019 | 5131 | 0.010 |
Why?
|
Tandem Mass Spectrometry | 1 | 2008 | 1197 | 0.010 |
Why?
|
Glomerular Filtration Rate | 1 | 2010 | 2228 | 0.010 |
Why?
|
Perioperative Care | 1 | 2009 | 1045 | 0.010 |
Why?
|
Sex Factors | 1 | 2015 | 10633 | 0.010 |
Why?
|
Referral and Consultation | 1 | 1992 | 3628 | 0.010 |
Why?
|
Lung Diseases, Obstructive | 1 | 1999 | 311 | 0.010 |
Why?
|
Recurrence | 1 | 2010 | 8513 | 0.010 |
Why?
|
Veins | 1 | 2001 | 769 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2000 | 20776 | 0.010 |
Why?
|
Antifungal Agents | 1 | 2001 | 761 | 0.010 |
Why?
|
Arteries | 1 | 2001 | 1126 | 0.010 |
Why?
|
Young Adult | 1 | 2019 | 60131 | 0.010 |
Why?
|
Age of Onset | 1 | 1999 | 3346 | 0.010 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2001 | 2276 | 0.010 |
Why?
|
Antirheumatic Agents | 1 | 1999 | 1381 | 0.000 |
Why?
|
Radiography | 1 | 1999 | 6991 | 0.000 |
Why?
|
Phenotype | 1 | 1999 | 16731 | 0.000 |
Why?
|
Asthma | 1 | 1999 | 6293 | 0.000 |
Why?
|
Animals | 1 | 2001 | 169335 | 0.000 |
Why?
|